Approaches for transplanting the sensitized patient: Biology versus pharmacology

Nephrology Dialysis Transplantation

Volumn 23, Issue 8, 2008, Pages 2454-2457

  Gebel, Howard M ^a   Bray, Robert A ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Alloimmunized; Histocompatibility; Renal transplantation

Indexed keywords

ALEMTUZUMAB; HLA ANTIBODY; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ALLOIMMUNIZATION; ANTIBODY SPECIFICITY; COST BENEFIT ANALYSIS; DESENSITIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; KIDNEY DONOR; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ANTILYMPHOCYTE SERUM; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; TRANSPLANTATION IMMUNOLOGY;

EID: 48749097781     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn108     Document Type: Review

References (35)

1. Patel R, Terasaki PI. Significance of a positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735
2. UNOS Annual Report 2006 http://www.ustransplanbt.org/annual_report
3. Bray RA, Nolen JD L, Larsen C et al. Transplanting the highly sensitized patient: the Emory Algorithm. Am J Transplant 2006; 2307-2315
4. Duquesoy R, Howe J, Takemoto S. HLA Matchmaker: a molecularly based algorithm for histocompatibility determination IV: an alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003; 75: 889-897
5. Monien S, Salama A, Schonemann C. ELISA methods detect HLA antibodies with variable sensitivity. Int J Immunogenet 2006; 33: 163-166
6. Bray RA, Nickerson P, Kerman R et al. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 2004; 29: 41-53
7. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor reactive HLA specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 2002; 3: 1488-1500
8. Cesbron-Gautier A, Simon P, Achard L et al. Luminex technology for HLA typing by PCR-SSO and identification of HLA antibody specificities. Ann Biol Clin 2004; 62: 93-98
9. Pei R, Lee J, Neng-Jen S et al. Single human leukocyte antigen flow cytometry beads for the accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43-49
10. Zangwill S, Ellis T, Stendahl T et al. Practical application of the virtual crossmatch. Pediatr Transplant 2007; 11: 650-654
11. Bielmann D, Honger G, Lutz D et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplantat 2007; 7: 626-632
12. McLaughlin K, Manns B, Nickerson P. The routine use of high resolution immunological screening of recipients of primary deceased donor renal allografts is cost effective. Transplantation 2006; 81: 1278-1284
13. Claas Frans HJ, Dankers Marlies K, Oudshoorn, Machteld et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transplant Immunol 2005; 14: 187-191
14. Goodman R, Taylor C, O'Rourke C et al. Utility of HLA Matchmaker and single-antigen HLA antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation. Transplantation 2006; 61: 1331-1336
15. Claas FH, Witvliet MD, Duquesnoy RJ et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78: 190-193
16. Segev DL, Gentry Se, Warren DS et al. Kidney paired donation and optimizing the use of love donor organs. JAMA 2005; 293: 1883-1890
17. Woodle E Steve. The potential of paired donation programs: modeling and reality. Am J Transplant 2005; 5: 1787-1788
18. Roth AE, Sonmez T, Unver MU et al. Utilizing list exchange and nondirected donation through 'chain' paired kidney donations. Am J Transplant 2006; 6: 2694-2705
19. Nashan Bjorn. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. Biodrugs 2005; 19: 39-46
20. Buhaescu Irina, Segall Liviu, Goldsmith David et al. New immunosuppressive therapies in renal transplantation: monoclonal antibodies. J Nephrol 2005; 18: 529-536
21. Vincenti F, de Andres A, Becker T et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int 2006; 19: 446-457
22. Webster A, Pankhurst T, Rinaldi F et al. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev 2006; CD004756
23. Anglicheau D, Loupy A, Suberbielle C et al. Posttransplant prophylactic intravenous immunolglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant 2007; 7: 1185-1192
24. Akalin Enver, Watschinger Bruno. Antibody-mediated rejection. Semin Nephrol 2007; 27: 393-407
25. Gloor J. Kidney transplantation in the hyperimmunized patient. Contrib Nephrol 2005; 146: 11-21
26. Jordan SC, Vo AA, Peng A et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients [see comment]. Am J Transplant 2006; 6: 459-466
27. Haas M, Montgomery RA, Segev DL et al. Sub-clinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-585
28. Warren DS, Simpkins CE, Cooper M et al. Modulating Alloimmune responses with plasmapheresis and IVIG. Curr Drug Target Cardiovasc Hematol Disord 2005; 5: 214-222
29. Montgomery Robert A, Zachary Andrea A. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535-542
30. Jordan Stanley C, Pescovitz Mark D. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006; 1: 421-432
31. Stegall MD, Gloor J, Winters JL et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351
32. Zachary Andrea A, Montgomery Robert A, Leffell Mary S. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364-370
33. Zou y, Stastny P, Susal C et al. Antibodies against MICA antigens and kidney transplant rejection. N Eng J Med 2007; 357: 1293-1300
34. Mizutani K, Terasaki P, Bignon JD et al. Association of kidney transplant failure and antibodies against MICA. Hum Immunol 2006; 67: 683-691
35. Leffell Mary S, Montgomery Robert A, Zachary Andrea A. The changing role of antibody testing in transplantation. Clin Transpl 2005; 259-271